Supplements

The National Burden of Preventable Adverse Drug Events Associated with Inpatient Injectable Medications
Genomic Testing and the Quality of Care: Exploring the Impact of Healthcare Reform
New Directions in the Treatment of Multiple Myeloma: Reports on Carfilzomib-Based Therapy from ASH 2012
Management of Multiple Sclerosis: Building Consensus between Healthcare Providers and Payers
Population Health Management in Patients with Type 2 Diabetes - Part 2
Tradjenta® (linagliptin) Tablets A Single-Dose Option for Adult Patients with Type 2 Diabetes
Population Health Management in Patients with Type 2 Diabetes - Part 1
Payer's Guide to New FDA Approvals
Management of Multiple Sclerosis: Building Consensus between Healthcare Providers and Payers
Payer Perspective ASH* 2011 Update: Strategies for Value-Based Care for Patients with Myelofibrosis
Anticoagulation Therapy in Atrial Fibrillation: Clinical and Economic Perspectives
Emerging Models of Healthcare Delivery and Payment: Stroke Prevention in Patients with Atrial Fibrillation
Payer Implications of Clinical Practice Guideline Concordance in Type 2 Diabetes and Chronic Kidney Disease
The Taxanes for Metastatic Breast Cancer: Total Cost of Care Considerations
Tradjenta™ (linagliptin) Tablets A New Type 2 Diabetes Treatment Option for Adult Patients with Inadequate Glycemic Control: Clinical Trials Review, Part 2
Tradjenta™ (linagliptin) Tablets A New Type 2 Diabetes Treatment Option for Patients with Inadequate Glycemic Control Clinical Trial Review, Part 1
Payers’ Guide to New FDA Approvals
ACAAI 2010: Payers’ Perspectives
Stakeholder Perspectives In Diabetes Management For Patients With Renal Impairment - Part 5
Stakeholder Perspectives In Diabetes Management For Patients With Renal Impairment - Part 4
ACCP 2010: Payers' Perspectives
ASH 2010: Payer's Perspectives
Does Implementing an OTC PPI Benefit Design Change Make Sense?
Stakeholder Perspectives In Diabetes Management For Patients With Renal Impairment - Part 3
ADA 2010: PAYERS’ PERSPECTIVES
Stakeholder Perspectives In Diabetes Management For Patients With Renal Impairment - Part 2
Prescription Drug Benefit Cost and Plan Design Report Supplement, Part 4
Stakeholder Perspectives In Diabetes Management For Patients With Renal Impairment - Part 1
Drug Update: A Complete Resource for New Drug Approvals and Indications in 2009
Prescription Drug Benefit Cost and Plan Design Report Supplement, Part 3
A Wellness-Based Healthcare System for Chronic Diseases: Prevention, Intervention, and Innovation
Optimizing Outcomes in Asthma through a Pay-for-Quality- Performance Program
Prescription Drug Benefit Cost and Plan Design Report Supplement, Part 2
Prescription Drug Benefit Cost and Plan Design Report Supplement, Part 1
Savella (Milnacipran HCl): A New Option for the Management of Fibromyalgia
TIA and Recurrent Stroke: Prevention and Treatment Strategies
Clinical and Cost Benefits of Abraxane for Breast Cancer Therapy
Drug Update: A Complete Resource for New Drug Approvals and Indications in 2008
Evidence-Based Approach to Methicillin-Resistant Staphylococcus aureus: Epidemiology, Pharmacotherapy, and Prevention Strategies
The Return to Deep Science: Pharmaceutical Research & Development in a Value-Based Healthcare System
The Strategic Role of Compendia in Cancer Drug Coverage, Part 2
Drug Delivery Systems for Administration of Inhaled Therapies in Patients with Chronic Obstructive Pulmonary Disease